Headlines about ImmunoGen (NASDAQ:IMGN) have been trending somewhat positive this week, according to Accern. The research firm scores the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ImmunoGen earned a news sentiment score of 0.15 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 46.5616123568527 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Here are some of the media headlines that may have effected Accern’s analysis:

A number of research firms recently issued reports on IMGN. Zacks Investment Research upgraded shares of ImmunoGen from a “hold” rating to a “buy” rating and set a $6.50 target price for the company in a report on Tuesday, October 31st. Leerink Swann restated a “buy” rating on shares of ImmunoGen in a report on Tuesday, August 29th. BidaskClub upgraded shares of ImmunoGen from a “hold” rating to a “buy” rating in a report on Saturday, August 26th. Cantor Fitzgerald restated a “hold” rating and issued a $5.00 target price on shares of ImmunoGen in a report on Monday, September 25th. Finally, ValuEngine downgraded shares of ImmunoGen from a “hold” rating to a “sell” rating in a report on Thursday, September 21st. Two research analysts have rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $7.83.

ImmunoGen (NASDAQ IMGN) opened at $6.09 on Friday. The company has a quick ratio of 2.78, a current ratio of 2.81 and a debt-to-equity ratio of -0.03. ImmunoGen has a 12-month low of $1.53 and a 12-month high of $8.84.

ImmunoGen (NASDAQ:IMGN) last announced its quarterly earnings results on Friday, November 3rd. The biotechnology company reported ($0.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.42). The business had revenue of $8.50 million for the quarter, compared to analysts’ expectations of $26.09 million. The firm’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same quarter last year, the business posted ($0.51) earnings per share. equities analysts forecast that ImmunoGen will post -0.98 earnings per share for the current year.

In other ImmunoGen news, VP Craig Barrows sold 14,600 shares of ImmunoGen stock in a transaction that occurred on Wednesday, September 13th. The shares were sold at an average price of $6.95, for a total transaction of $101,470.00. Following the transaction, the vice president now directly owns 51,100 shares of the company’s stock, valued at $355,145. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders own 6.51% of the company’s stock.

WARNING: “ImmunoGen (IMGN) Receiving Somewhat Favorable Press Coverage, Accern Reports” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another publication, it was stolen and republished in violation of United States & international trademark and copyright laws. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/12/03/immunogen-imgn-receiving-somewhat-favorable-press-coverage-accern-reports.html.

ImmunoGen Company Profile

ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.

Insider Buying and Selling by Quarter for ImmunoGen (NASDAQ:IMGN)

Receive News & Stock Ratings for ImmunoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen Inc. and related stocks with our FREE daily email newsletter.